Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

Christine R Jenkins, Dirkje S Postma, Antonio R Anzueto, Barry J Make, Stefan Peterson, Göran Eriksson, Peter M Calverley

Research output: Contribution to journalArticlepeer-review

24 Citations (SciVal)
142 Downloads (Pure)

Abstract

Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.
Original languageEnglish
Article number97
JournalBMC Pulmonary Medicine
Volume15
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Respiratory Medicine and Allergy

Fingerprint

Dive into the research topics of 'Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.'. Together they form a unique fingerprint.

Cite this